AIPL1

AIPL1 Full Name

aryl hydrocarbon receptor interacting protein-like 1

AIPL1 Introduction

Aryl Hydrocarbon Receptor Interacting Protein Like 1 is a protein-coding gene that encodes a regulatory protein involved in cellular signaling and protein stability. It is predominantly expressed in specific tissues, with prominent presence in cells of the visual system. As a regulatory molecule, it interacts with various proteins to modulate their function and stability, playing a key role in maintaining cellular homeostasis and specialized tissue function. Its unique interaction capabilities make it an important component of cellular regulatory networks, particularly in tissues with highly specialized functions.It possesses motifs that support protein-protein interactions, allowing it to form stable complexes with key regulatory molecules. These structural traits are critical for its role in maintaining protein stability and regulating cellular signaling pathways. The protein's structure also facilitates post-translational modifications that adjust its binding affinity and regulatory activity, adapting to varying cellular needs.

Figure 1.The structure of AIPL1.

Gene Therapy and Emerging Treatments for AIPL1 Deficiency
The small size of the AIPL1 coding sequence makes it an attractive candidate for gene replacement therapy using adeno-associated virus vectors. Preclinical studies in mouse models of AIPL1 deficiency have demonstrated that subretinal injection of adeno-associated virus carrying the human AIPL1 gene under a photoreceptor-specific promoter restores AIPL1 expression in treated areas of the retina, rescues phosphodiesterase levels and localization, and preserves photoreceptor structure and function. The therapeutic window is limited, as photoreceptor degeneration begins early and progresses rapidly, so treatment must be administered before extensive cell loss has occurred. In animal models, treatment at postnatal day ten to fourteen, which corresponds roughly to human infancy, is effective, while treatment at later stages is less beneficial. Based on these promising results, a clinical trial of AAV-mediated AIPL1 gene therapy for Leber congenital amaurosis type 4 is in planning or early development.

Biomarker and Diagnostic Applications
The restricted expression pattern of AIPL1 makes it a useful biomarker for photoreceptor cells and for retinal development. In research settings, AIPL1 antibodies are used to identify and quantify photoreceptor cells in retinal sections, to assess the integrity of the photoreceptor layer in animal models of retinal degeneration, and to monitor the efficacy of gene therapy and other treatments. In clinical diagnostic laboratories, immunostaining of retinal biopsies for AIPL1 is not routinely performed, as genetic testing has largely replaced protein-based diagnostics. However, in cases where genetic testing is inconclusive, immunohistochemical detection of AIPL1 in postmortem retinal tissue can confirm the diagnosis. AIPL1 expression has also been detected in certain retinoblastoma cell lines and in some retinal tumors, though the significance of this finding is unclear. Beyond the retina, AIPL1 is not expressed in normal tissues, but it has been reported to be aberrantly expressed in some non-retinal cancers, including lung cancer and melanoma, as a cancer-testis antigen. This has raised the possibility of using AIPL1 as a target for cancer immunotherapy, though the expression levels in tumors are low and the fraction of patients expressing AIPL1 is small.

Alternate Names for AIPL1

AIPL1; aryl hydrocarbon receptor interacting protein-like 1; LCA4; AIPL2; aryl-hydrocarbon-interacting protein-like 1